Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 7/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | GCGR | P47871 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18800779 | 0.94 | XDH (0.47) | NPC1RAB9ABTKXDHMCL1 | |
| SCHEMBL18800677 | 0.93 | MCL1 (0.46) | NPC1RAB9ABTKXDHMCL1 | |
| SCHEMBL18800649 | 0.91 | MEN1 (0.46) | NPC1RAB9ATNK2BTKXDH | |
| SCHEMBL18800407 | 0.89 | F2 (0.49) | NPC1RAB9ABTKXDHMCL1 | |
| SCHEMBL18800472 | 0.89 | XDH (0.46) | NPC1RAB9ATNK2BTKXDH | |
| SCHEMBL18800785 | 0.88 | MCL1 (0.50) | NPC1RAB9ATNK2BTKXDH | |
| SCHEMBL18800717 | 0.88 | BTK (0.45) | NPC1RAB9ABTKXDHMCL1 | |
| SCHEMBL18800660 | 0.88 | SCN9A (0.43) | TNK2BTKXDHMCL1SCN9A | |
| SCHEMBL18800656 | 0.87 | BTK (0.55) | NPC1RAB9ABTKXDHSCN9A | |
| SCHEMBL16168183 | 0.86 | LTA4H (0.47) | NPC1RAB9ABTKXDHMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2789615-B1 | Azaindazoles as Btk kinase modulators and use thereof | BRISTOL MYERS SQUIBB CO (US) | 2017-05-03 | — | — | EP | disclosed |